HC Wainwright reiterated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a $5.00 price objective on the biopharmaceutical company’s stock.
Separately, StockNews.com started coverage on Sangamo Therapeutics in a report on Sunday, July 28th. They issued a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $2.67.
View Our Latest Stock Report on Sangamo Therapeutics
Sangamo Therapeutics Stock Performance
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The firm had revenue of $0.36 million during the quarter, compared to analyst estimates of $11.40 million. Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. On average, sell-side analysts forecast that Sangamo Therapeutics will post -0.47 earnings per share for the current year.
Hedge Funds Weigh In On Sangamo Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SGMO. Wasatch Advisors LP lifted its holdings in shares of Sangamo Therapeutics by 62.4% in the first quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock valued at $13,493,000 after purchasing an additional 7,734,400 shares in the last quarter. Acadian Asset Management LLC raised its position in Sangamo Therapeutics by 4.0% in the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock valued at $3,311,000 after buying an additional 192,385 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after acquiring an additional 1,528,600 shares in the last quarter. Marshall Wace LLP boosted its position in Sangamo Therapeutics by 56.3% during the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 207,476 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Sangamo Therapeutics during the 1st quarter worth approximately $331,000. 56.93% of the stock is owned by institutional investors and hedge funds.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
See Also
- Five stocks we like better than Sangamo Therapeutics
- Learn Technical Analysis Skills to Master the Stock Market
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Find and Profitably Trade Stocks at 52-Week Lows
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Overbought Stocks Explained: Should You Trade Them?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.